Histamine Receptor 1 and 2 Antagonists Alter Biodistribution of Radioiodine

Oliver Edwards, Ellen D. Yakish, Liming Wang, Qi Wu, John M. Hoffman, Kathryn A. MortonJournal of Nuclear Medicine Technology 2015 · DOI

Abstract

H1 and H2 blockers alter the biodistribution of radioiodine in the rat. Although the findings remain to be confirmed in humans, these drugs could increase radiation exposure to nontarget tissues, particularly the stomach and salivary tissue, during $^{131}$I therapy. Consideration should be given toward avoiding the elective use of these drugs during radioiodine therapy.

Introduction

Radioiodine ($^{131}$I) is a cornerstone of treatment for hyperthyroidism and thyroid cancer because the thyroid naturally "traps" iodine. However, other tissues—like the salivary glands and the gastric mucosa—also express the sodium-iodide symporter (NIS) and take up iodine, leading to common side effects like dry mouth (sialadenitis) and stomach irritation (gastritis).

Many patients undergoing these treatments are also taking histamine receptor antagonists, such as H1 blockers (for allergies) or H2 blockers (for acid reflux). This study investigates whether these common medications interfere with the thyroid's trapping mechanism or increase iodine uptake in non-target organs, which could inadvertently increase radiation doses to healthy tissue or skew diagnostic results.

Methods

The researchers used a cohort of 32 adult male Sprague-Dawley rats, divided into four treatment groups:

  1. Control: No drug administered.
  2. H1 Blocker: Promethazine (commonly used for allergies/nausea).
  3. H2 Blocker: Famotidine (commonly used for acid reflux).
  4. PPI: Esomeprazole (a proton pump inhibitor for reflux).

Drugs were administered via daily subcutaneous injections starting one day before a single injection of $^{131}$I. The researchers then performed $\gamma$-well counting on resected tissues (thyroid, salivary glands, stomach, liver, and blood) at 1 day and 8 days post-injection to evaluate both immediate impact and longer-term clearance patterns.

Results

Thyroid Uptake

Promethazine (H1 blocker) was the only drug to significantly increase uptake in the thyroid itself. It showed a 32% increase at 1 day and a 52% increase at 8 days compared to controls. This finding is critical because it could lead to an overestimation of thyroid function or incorrect dose calculations in clinical settings.

Figure 1: Radioiodine uptake in the whole thyroid at 1 and 8 days post-injection across treatment cohorts.

Salivary Glands and Stomach

The most dramatic effects were observed at the 8-day mark. While initial differences were modest, by day 8, salivary gland uptake in drug-treated rats was 4.5 to 5.5 times higher than in controls. Specifically, Famotidine caused a 4.52-fold increase and Promethazine caused a 5.57-fold increase in $^{131}$I retention.

Figure 2: Radioiodine retention in salivary glands (%ID/g) at 1 and 8 days, showing significant increases with H1 and H2 blockers.

Similarly, Promethazine increased gastric uptake by 47% at 1 day and 146% at 8 days, significantly increasing the potential radiation dose to the stomach mucosa.

Liver and Blood

The liver showed a massive increase in radioiodine retention at 8 days (roughly 10-fold) for both H1 and H2 blockers. Interestingly, blood levels of $^{131}$I remained consistent across all groups, indicating that the drugs change where the iodine is sequestered rather than the total amount remaining in the system. Notably, the PPI Esomeprazole did not significantly alter radioiodine distribution in any tested organ.

Discussion and Clinical Implications

The primary limitation of this study is the use of a rat model and subcutaneous administration. However, the physiological similarities in iodine metabolism suggest these findings may translate to humans. The "8-day surge" in non-target tissues like the salivary glands and liver is particularly concerning for patients undergoing high-dose $^{131}$I therapy, as it may exacerbate side effects like sialadenitis.

The authors recommend that clinicians consider having patients withhold H1 and H2 blockers for at least one week (approximately 4–5 elimination half-lives) before radioiodine procedures. For patients requiring acid suppression, PPIs like Esomeprazole appear to be a safer alternative as they did not interfere with biodistribution.

Conclusion

H1 and H2 receptor antagonists significantly alter the biodistribution of radioiodine, increasing exposure to non-target tissues. While further human clinical trials are needed, avoiding these medications during therapy may improve safety and diagnostic accuracy.

Summary updated

Abstract

H1 and H2 blockers alter the biodistribution of radioiodine in the rat. Although the findings remain to be confirmed in humans, these drugs could increase radiation exposure to nontarget tissues, particularly the stomach and salivary tissue, during (131)I therapy and consideration should be given toward avoiding the elective use of these drugs during radioiodine therapy.
BibTeX
@article{edwards2015histamine,
  author = {Oliver Edwards and Ellen D. Yakish and Liming Wang and Qi Wu and John M. Hoffman and Kathryn A. Morton},
  title = {{Histamine Receptor 1 and 2 Antagonists Alter Biodistribution of Radioiodine}},
  journal = {Journal of Nuclear Medicine Technology},
  year = {2015},
  doi = {10.2967/jnmt.115.160697},
}
Figure